Symptomtext
Patient received the expired fluzone dose with no reported adverse event; Initial information received on 21-Oct-2022 regarding an unsolicited valid non-serious case received from other health professional. This case is linked to cases 2022SA442254 and 2022SA443423(CLUSTER). This case involves a 17years old female patient to whom expired fluzone dose with no reported adverse event while receiving vaccine influenza quadrival A-B vaccine [Fluzone Quadrivalent]. The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication and family history were not provided. On 20-Oct-2022, the patient received suspect INFLUENZA QUADRIVAL A-B VACCINE at a total dose of 0.5 ml (lot UJ776AA, expiry date: 30-Jun-2022) (strength: standard) via intramuscular route in the left deltoid for immunization. On 20-Oct-2022 the patient developed a non-serious patient received the expired fluzone dose with no reported adverse event (expired product administered) (same day latency) following the administration of INFLUENZA QUADRIVAL A-B VACCINE. Action taken: Not applicable. Outcome: Unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.